Nd:YAG Laser Combined With Injection Sclerotherapy Versus Diode Laser in the Treatment of Reticular Veins and Telangiectasias Using CLaCS Technique

NCT07678697 | Recruiting

• 1 other identifier: IRB 00006379 (17/05/2026)
• Study Type: interventional
• Target: 80
• Locations: 1 country
• Sites: 1

Brief Summary

This study aims to compare the efficacy (in terms of vein clearance) and safety of Nd:YAG laser combined with injection sclerotherapy versus diode laser combined with injection sclerotherapy in the treatment of reticular veins and telangiectasias using the Cryo-Laser and Cryo-Sclerotherapy (CLaCS) technique.

Conditions

Nd:YAG Laser; Sclerotherapy; Diode Laser; Reticular Veins; Telangiectasias; CLaCS Technique

Outcome Measures

Primary Outcomes (1)

• Degree of vein clearance

  Degree of vein clearance will be assessed by immediate endpoint response during laser application, defined as either instantaneous disappearance of the vein or an immediate change in vein color.

  6 months postoperatively

Secondary Outcomes (5)

• Degree of pain

  6 months postoperatively

• Degree of patient satisfaction

  6 months postoperatively

• Incidence of complications

  6 months postoperatively

• Number of treatment sessions required

  6 months postoperatively

• Recurrence rate

  6 months postoperatively

Study Arms (2)

Group A (Nd:YAG Group):

EXPERIMENTAL

Patients will receive Nd:YAG laser (1064 nm) + injection sclerotherapy (CLaCS).

Device: Nd:YAG laser

Group B (Diode Group)

EXPERIMENTAL

Patients will receive Diode laser (980 nm) + injection sclerotherapy (CLaCS).

Drug: Diode laser

Interventions

Nd:YAG laser DEVICE

Patients will receive Nd:YAG laser (1064 nm) + injection sclerotherapy (CLaCS).

Group A (Nd:YAG Group):

Diode laser DRUG

Patients will receive Diode laser (980 nm) + injection sclerotherapy (CLaCS).

Group B (Diode Group)

Eligibility Criteria

• Age: 18 Years - 60 Years
• Sex: all
• Healthy Volunteers: No
• Age Groups: Adult (18-64)

You may qualify if:

• Patients aged 18-60 years.
• Both sexes.
• Presence of reticular veins and/or telangiectasias (CEAP classification C1).
• Fitzpatrick skin types II-V.
• Patients seeking cosmetic treatment.

You may not qualify if:

• Pregnancy or lactation.
• History of deep vein thrombosis.
• Coagulation disorders.
• Allergy to sclerosant agents.
• Active skin infection at treatment site.
• Previous treatment of target veins within 6 months.
• Great saphenous vein or short saphenous vein incompetence.
• Deep venous insufficiency or thrombosis.
• Abnormal venous duplex findings.

Sponsors & Collaborators

• Ain Shams University: lead

Study Sites (1)

Ain Shams University

Cairo, 11591, Egypt

RECRUITING

MeSH Terms

Conditions

Telangiectasis

Interventions

Lasers, Semiconductor

Condition Hierarchy (Ancestors)

Vascular Diseases; Cardiovascular Diseases

Intervention Hierarchy (Ancestors)

Lasers; Optical Devices; Equipment and Supplies; Radiation Equipment and Supplies

Central Study Contacts

Mohamed A Hagag, MD

CONTACT

00201126560324; hagagmohamed@med.asu.edu.eg

Study Design

• Study Type: interventional
• Phase: not applicable
• Allocation: RANDOMIZED
• Masking: DOUBLE
• Who Masked: PARTICIPANT, OUTCOMES ASSESSOR
• Purpose: TREATMENT
• Intervention Model: PARALLEL
• Sponsor Type: OTHER
• Responsible Party: PRINCIPAL INVESTIGATOR
• PI Title: Lecturer of Vascular Surgery, Faculty of Medicine, Ain Shams University, Cairo, Egypt.

Study Record Dates

• First Submitted: June 25, 2026
• First Posted: July 1, 2026
• Study Start: June 1, 2026
• Primary Completion (Estimated): December 1, 2026
• Study Completion (Estimated): December 1, 2026
• Last Updated: July 1, 2026

Record last verified: 2026-06

Data Sharing

• IPD Sharing: Will share
• Shared Documents: STUDY PROTOCOL
• Time Frame: After the end of study for one year.
• Access Criteria: The data will be available upon a reasonable request from the corresponding author.

Locations

EG (1)